Rx Rundown: Merck, Biogen, Pfizer and more
Deals: Sage Therapeutics turned down Biogen’s buyout offer and will look at other options. Lantheus Holdings acquired Massachusetts-based Evergreen Theragnostics for $250 million upfront. AB2 inked a $36 million deal with Nippon Shinyaku. Cancer Research …